# STIMULUS-MDS1 (NCT03946670)

> A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03946670
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Myelodysplastic Syndromes
- Interventions: MBG453; Placebo; Hypomethylating agents
- Enrollment: 127
- Primary outcome: Complete Remission (CR) Rate
- Primary outcome: Progression Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 11
- YouTube: 3
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=stimulus-mds1-nct03946670

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03946670", "email": "<work email>"}; the inbox owner confirms by the emailed link.